Epidemiology of Neuroendocrine Neoplasms in the US
Incidence and prevalence of NENs continue to rise driven by increased diagnosis of early stage disease. Survival for NENs has also improved over time.
Authors
- Daniel M. Halperin (ORCID: https://orcid.org/0000-0002-3113-930X)
- Arvind N. Dasari (ORCID: https://orcid.org/0000-0001-5271-9744)
- Katrine L. Wallace (ORCID: https://orcid.org/0000-0002-5003-0617)
- Beth Chasen
- James C. Yao (ORCID: https://orcid.org/0000-0002-1875-3962)
- Jessica Maxwell (ORCID: https://orcid.org/0000-0003-4913-6518)
- Pamela L. Kunz (ORCID: https://orcid.org/0000-0002-9901-954X)
- Simron Singh (ORCID: https://orcid.org/0000-0002-5179-7043)
Institutions
- Sunnybrook Health Science Centre (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- University of Toronto (CA)
- Yale Cancer Center (US)
- University of Illinois Chicago (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.15798
- Citations
- 41
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 55.52
Funders
- Amgen
- Sanofi
- Exelixis
- Advanced Accelerator Applications
- Ipsen
- National Institutes of Health
- University of Texas MD Anderson Cancer Center